ArticleNew microbes and new infections2026
Experimental adaptation of pigeon rotavirus A (pRVA) in human colorectal cancer cells reveals interferon-driven host responses and immune checkpoint modulation.
Article in New microbes and new infections, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oncolytic viruses selectively target cancer cells, which is beneficial for combination therapy with immune checkpoint-targeted therapies or for direct oncolysis. Among the increasing number of cancer cases, colorectal cancer (CRC) is one of the leading causes of death. Many studies have shown that mammalian-origin rotavirus can be repurposed as an oncolytic virus for CRC. Rotaviruses can evade inflammatory immune responses upon infection and exhibit specificity for cancer cells, a highly suitable characteristic for oncolytic viruses. In this study, we aim to explore the experimental infection of pigeon rotavirus A (pRVA), an infectious disease that causes young pigeon disease syndrome (YPDS) in pigeons. Here, we report the first case of an avian-origin rotavirus as an oncolytic virus against colorectal cancer cells, HT29 and Caco2. The pRVA showed higher infectivity and selectivity in HT29 cells than in Caco2 cells, with evident cytopathic effects, including apoptosis. The mRNA expression revealed that pRVA activates the interferon-mediated pathway while regulating NF-κB signaling, allowing prolonged detection of viral RNA and oncolysis. Induction of immune checkpoints upon pRVA infection enables the infected cell to evade immune recognition, thereby promoting delayed viral RNA clearance while enhancing oncolysis. The pRVA infection selectively modulates toll-like receptor (TLRs), viral RNA-sensing endosomal TLRs, suggesting coordinated innate immune sensing and immune checkpoint regulation. Inflammatory cytokines, including IL-6sR, IP-10, MIP-1γ, and RANTES, were inhibited after infection, suggesting a unique immune evasion by the rotavirus. This immune modulation may facilitate sustained viral RNA presence and support the potential utility of pRVA as an oncolytic virus.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.